Enovis (NYSE:ENOV) Upgraded to “Strong-Buy” at Zacks Research

Enovis (NYSE:ENOV) was upgraded by stock analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued to investors on Wednesday,Zacks.com reports.

A number of other equities research analysts have also recently commented on the stock. Evercore reaffirmed an “outperform” rating on shares of Enovis in a report on Monday, January 12th. Wells Fargo & Company boosted their target price on Enovis from $41.00 to $42.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. BTIG Research upped their price target on Enovis from $41.00 to $43.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Needham & Company LLC increased their price target on Enovis from $49.00 to $52.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Finally, UBS Group restated a “buy” rating and issued a $50.00 price objective on shares of Enovis in a research note on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $47.43.

Enovis Trading Down 5.8%

NYSE ENOV opened at $24.29 on Wednesday. The business’s fifty day moving average is $24.15 and its 200-day moving average is $28.08. The company has a debt-to-equity ratio of 0.85, a current ratio of 2.02 and a quick ratio of 1.04. The stock has a market capitalization of $1.39 billion, a price-to-earnings ratio of -1.17 and a beta of 1.46. Enovis has a one year low of $21.00 and a one year high of $40.69.

Enovis (NYSE:ENOV) last posted its quarterly earnings data on Thursday, February 26th. The company reported $0.95 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.81 by $0.14. The business had revenue of $575.76 million during the quarter, compared to the consensus estimate of $584.30 million. Enovis had a negative net margin of 52.69% and a positive return on equity of 8.74%. The firm’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter last year, the company posted $0.98 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Equities research analysts predict that Enovis will post 2.79 EPS for the current year.

Insiders Place Their Bets

In related news, EVP Daniel A. Pryor sold 999 shares of the stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $27.20, for a total transaction of $27,172.80. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Oliver Engert bought 1,000 shares of the business’s stock in a transaction on Friday, February 27th. The stock was bought at an average price of $25.50 per share, with a total value of $25,500.00. Following the purchase, the insider owned 43,640 shares in the company, valued at $1,112,820. This trade represents a 2.35% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders have purchased 2,250 shares of company stock worth $56,545. 2.70% of the stock is currently owned by corporate insiders.

Institutional Trading of Enovis

A number of hedge funds and other institutional investors have recently bought and sold shares of ENOV. Arax Advisory Partners bought a new position in Enovis in the 4th quarter valued at $29,000. Farther Finance Advisors LLC increased its holdings in shares of Enovis by 42.8% in the third quarter. Farther Finance Advisors LLC now owns 1,224 shares of the company’s stock worth $37,000 after purchasing an additional 367 shares during the period. EverSource Wealth Advisors LLC raised its position in shares of Enovis by 125.4% in the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after buying an additional 707 shares in the last quarter. Elevation Point Wealth Partners LLC bought a new stake in Enovis during the second quarter valued at $46,000. Finally, SJS Investment Consulting Inc. boosted its stake in Enovis by 30,340.0% during the third quarter. SJS Investment Consulting Inc. now owns 1,522 shares of the company’s stock valued at $46,000 after buying an additional 1,517 shares during the period. Institutional investors own 98.45% of the company’s stock.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.